Subscribe
astrazeneca-istock-458250071-fotonen-
Fotonen / iStockphoto.com
30 July 2020Big PharmaMuireann Bolger

AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment

Biopharmaceutical company  AstraZeneca has struck a deal with Japanese pharmaceutical company  Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
AstraZeneca announces new R&D, AI centres in China
11 November 2019   AstraZeneca is planning to build a new global research and development centre in China.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
AstraZeneca announces new R&D, AI centres in China
11 November 2019   AstraZeneca is planning to build a new global research and development centre in China.

More on this story

Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Big Pharma
AstraZeneca announces new R&D, AI centres in China
11 November 2019   AstraZeneca is planning to build a new global research and development centre in China.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits